{
    "name": "risdiplam",
    "comment": "Rx",
    "other_names": [
        "Evrysdi"
    ],
    "classes": [
        "SMN Splicing Modifiers"
    ],
    "source": "https://reference.medscape.com/drug/evrysdi-risdiplam-4000042",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy and fetal/neonatal/infant outcomes in women exposed to EVRYSDI during pregnancy; physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-833- 760-1098 or visiting ",
            "Data are unavailable on developmental risk associated with the use in pregnant females",
            "May cause embryofetal harm when administered to pregnant females",
            "Pregnancy testing recommended for females of reproductive potential before initiating"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "In animal studies, risdiplam administration during pregnancy or throughout pregnancy and lactation resulted in adverse effects on development (embryofetal mortality, malformations, decreased fetal body weights, and reproductive impairment in offspring) at or above clinically relevant drug exposure"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for at least 1 month after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Male fertility may be compromised by treatment",
                    "Counsel male patients of reproductive potential about potential reproductive effects",
                    "Male patients may consider sperm preservation before treatment"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are not available on presence in human milk, effects on breastfed infants, or effects on milk production",
            "Orally administered risdiplam was excreted in milk of lactating rats"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "MATE substrates",
                        "Avoid coadministration; if unable to avoid, monitor for drug-related toxicities and consider dosage reduction of the coadministered drug (based on the labeling of that drug) if needed",
                        "Based on in vitro data, risdiplam may increase plasma concentrations of drugs eliminated via MATE1 or MATE2-K (eg, metformin)"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "metformin",
            "description": {
                "common": "risdiplam will increase the level or effect of metformin by  decreasing elimination. Avoid or Use Alternate Drug. Risdiplam inhibits MATE1 and MATE2-K. If unable to avoid coadministration with MATE substrates, consider dosage reduction of MATE substrate."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Upper respiratory tract infection",
            "percent": null
        },
        {
            "name": "Pneumonia",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        }
    ]
}